See more : Bank Polska Kasa Opieki S.A. (PEO.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Hill-Rom Holdings, Inc. (HRC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hill-Rom Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Castile Resources Limited (CLRSF) Income Statement Analysis – Financial Results
- PepperLime Health Acquisition Corporation (PEPLW) Income Statement Analysis – Financial Results
- Mei Ah Entertainment Group Limited (0391.HK) Income Statement Analysis – Financial Results
- NOROO PAINT & COATINGS Co., Ltd. (090355.KS) Income Statement Analysis – Financial Results
- CenterPoint Energy, Inc. (CNP-PB) Income Statement Analysis – Financial Results
Hill-Rom Holdings, Inc. (HRC)
About Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.02B | 2.88B | 2.91B | 2.85B | 2.74B | 2.66B | 1.99B | 1.69B | 1.72B | 1.63B | 1.59B | 1.47B | 1.39B | 1.51B | 2.02B | 1.96B | 1.94B | 1.83B | 2.04B | 1.76B | 2.11B | 2.10B | 2.05B | 2.00B | 1.78B | 1.68B | 1.62B | 1.58B | 1.45B | 1.43B | 1.20B | 1.11B | 1.14B | 884.30M | 724.60M | 641.10M | 507.60M |
| Cost of Revenue | 1.43B | 1.41B | 1.48B | 1.45B | 1.42B | 1.40B | 1.11B | 906.20M | 935.90M | 879.60M | 810.40M | 753.00M | 759.00M | 838.20M | 1.14B | 1.11B | 1.05B | 921.00M | 1.14B | 1.01B | 1.25B | 1.27B | 1.27B | 1.17B | 1.03B | 908.00M | 1.01B | 939.20M | 634.80M | 646.60M | 555.60M | 508.90M | 596.90M | 410.40M | 328.50M | 286.90M | 265.80M |
| Gross Profit | 1.59B | 1.48B | 1.43B | 1.39B | 1.32B | 1.26B | 880.30M | 779.90M | 780.30M | 754.70M | 781.30M | 716.60M | 627.90M | 669.50M | 881.10M | 849.80M | 888.00M | 908.00M | 901.00M | 748.00M | 854.00M | 826.00M | 776.00M | 834.00M | 745.00M | 776.00M | 613.00M | 637.80M | 813.10M | 783.20M | 643.30M | 597.70M | 541.40M | 473.90M | 396.10M | 354.20M | 241.80M |
| Gross Profit Ratio | 52.61% | 51.20% | 49.01% | 48.95% | 48.13% | 47.34% | 44.28% | 46.25% | 45.47% | 46.18% | 49.09% | 48.76% | 45.27% | 44.41% | 43.54% | 43.29% | 45.82% | 49.64% | 44.12% | 42.57% | 40.53% | 39.41% | 37.91% | 41.68% | 41.95% | 46.08% | 37.73% | 40.44% | 56.16% | 54.78% | 53.66% | 54.01% | 47.56% | 53.59% | 54.66% | 55.25% | 47.64% |
| Research & Development | 144.90M | 136.50M | 139.50M | 135.60M | 133.70M | 133.50M | 91.80M | 71.90M | 70.20M | 66.90M | 63.80M | 58.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 995.60M | 929.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 517.30M | 22.80M | -1.40M | 3.10M | 394.00M | 6.00M | 9.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 99.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Operating Expenses | 1.14B | 1.07B | 1.08B | 1.03B | 1.01B | 986.80M | 756.00M | 620.20M | 619.70M | 563.30M | 565.80M | 532.90M | 517.30M | 566.70M | 603.00M | 532.20M | 998.00M | 588.00M | 582.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 540.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Cost & Expenses | 2.57B | 2.47B | 2.56B | 2.48B | 2.43B | 2.39B | 1.86B | 1.53B | 1.56B | 1.44B | 1.38B | 1.29B | 1.28B | 1.40B | 1.75B | 1.65B | 2.05B | 1.51B | 1.72B | 1.79B | 1.87B | 1.85B | 1.84B | 1.77B | 1.51B | 1.45B | 1.45B | 1.42B | 1.21B | 1.24B | 1.04B | 969.10M | 997.90M | 748.90M | 598.80M | 527.50M | 437.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 65.60M | 74.00M | 89.60M | 95.00M | 88.90M | 90.40M | 18.40M | 9.80M | 9.50M | 6.50M | 8.50M | 8.70M | 10.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 185.80M | 178.80M | 194.80M | 196.50M | 210.80M | 209.00M | 118.20M | 106.40M | 116.80M | 111.70M | 103.90M | 99.70M | 100.20M | 112.80M | 107.30M | 108.80M | 114.00M | 108.00M | 75.00M | 71.00M | 100.00M | 89.00M | 98.00M | 149.00M | 102.00M | 99.00M | 127.60M | 97.50M | 112.70M | 115.30M | 95.00M | 94.00M | 81.00M | 68.80M | 54.40M | 49.30M | 28.30M |
| EBITDA | 554.20M | 524.00M | 493.00M | 488.70M | 484.00M | 439.00M | 202.60M | 231.40M | 270.30M | 281.70M | 271.90M | 290.60M | -268.20M | 253.80M | 398.80M | 447.50M | 6.00M | 338.00M | 313.00M | 50.00M | 323.00M | 329.00M | 293.00M | 442.00M | 361.00M | 332.00M | 297.40M | 242.30M | 347.70M | 297.30M | 240.70M | 220.40M | 208.30M | 189.20M | 164.80M | 149.20M | 90.00M |
| EBITDA Ratio | 18.36% | 18.19% | 16.96% | 17.16% | 17.64% | 16.53% | 10.19% | 13.72% | 15.75% | 17.24% | 17.08% | 19.77% | -19.34% | 16.83% | 19.71% | 22.80% | 0.31% | 18.48% | 15.33% | 2.85% | 15.33% | 15.70% | 14.31% | 22.09% | 20.33% | 19.71% | 18.30% | 15.36% | 24.01% | 20.79% | 20.08% | 19.92% | 18.30% | 21.40% | 22.74% | 23.27% | 17.73% |
| Operating Income | 447.60M | 409.20M | 344.50M | 367.10M | 310.80M | 270.20M | 124.30M | 159.70M | 160.60M | 191.40M | 215.50M | 183.70M | 110.60M | 102.80M | 278.10M | 317.60M | -110.00M | 320.00M | 319.00M | -32.00M | 236.00M | 244.00M | 211.00M | 228.00M | 264.00M | 236.00M | 179.50M | 156.10M | 234.30M | 189.40M | 157.90M | 137.50M | 140.40M | 135.40M | 125.80M | 113.60M | 70.60M |
| Operating Income Ratio | 14.83% | 14.20% | 11.85% | 12.89% | 11.33% | 10.18% | 6.25% | 9.47% | 9.36% | 11.71% | 13.54% | 12.50% | 7.97% | 6.82% | 13.74% | 16.18% | -5.68% | 17.50% | 15.62% | -1.82% | 11.20% | 11.64% | 10.31% | 11.39% | 14.86% | 14.01% | 11.05% | 9.90% | 16.18% | 13.25% | 13.17% | 12.43% | 12.33% | 15.31% | 17.36% | 17.72% | 13.91% |
| Total Other Income/Expenses | -144.80M | -138.00M | -135.90M | -169.90M | -127.80M | -131.90M | -59.20M | -44.50M | -16.60M | -27.90M | -55.80M | -800.00K | -489.40M | -10.50M | 13.40M | 21.40M | -6.00M | -12.00M | -37.00M | -3.00M | -13.00M | -4.00M | -16.00M | 65.00M | -5.00M | -3.00M | -9.70M | -11.30M | -12.70M | -18.10M | -12.20M | -11.10M | -13.10M | -15.00M | -15.40M | -13.70M | -8.90M |
| Income Before Tax | 302.80M | 271.20M | 208.60M | 197.20M | 183.00M | 138.30M | 65.10M | 115.20M | 144.00M | 163.50M | 159.70M | 182.90M | -378.80M | 92.30M | 291.50M | 339.00M | -116.00M | 308.00M | 282.00M | -35.00M | 223.00M | 240.00M | 195.00M | 293.00M | 259.00M | 233.00M | 169.80M | 144.80M | 221.60M | 171.30M | 145.70M | 126.40M | 127.30M | 120.40M | 110.40M | 99.90M | 61.70M |
| Income Before Tax Ratio | 10.03% | 9.41% | 7.18% | 6.92% | 6.67% | 5.21% | 3.27% | 6.83% | 8.39% | 10.00% | 10.03% | 12.45% | -27.31% | 6.12% | 14.40% | 17.27% | -5.99% | 16.84% | 13.81% | -1.99% | 10.58% | 11.45% | 9.53% | 14.64% | 14.58% | 13.84% | 10.45% | 9.18% | 15.30% | 11.98% | 12.15% | 11.42% | 11.18% | 13.62% | 15.24% | 15.58% | 12.16% |
| Income Tax Expense | 54.30M | 48.20M | 56.40M | -55.20M | 50.70M | 15.50M | 18.30M | 54.60M | 39.00M | 42.70M | 26.20M | 56.90M | 26.20M | 25.20M | 100.90M | 117.50M | -20.00M | 120.00M | 100.00M | -25.00M | 53.00M | 86.00M | 71.00M | 109.00M | 102.00M | 93.00M | 79.90M | 55.30M | 89.10M | 65.80M | 56.50M | 50.70M | 52.30M | 50.70M | 53.00M | 49.40M | 28.90M |
| Net Income | 248.50M | 223.00M | 152.20M | 252.40M | 133.60M | 124.10M | 47.70M | 60.60M | 105.00M | 120.80M | 133.30M | 125.30M | -405.00M | 115.80M | 190.60M | 221.20M | -94.00M | 110.00M | 138.00M | -10.00M | 170.00M | 154.00M | 124.00M | 184.00M | 157.00M | 140.00M | 89.90M | 89.50M | 145.90M | 116.20M | 89.20M | 75.70M | 75.00M | 69.70M | 57.40M | 50.50M | 32.80M |
| Net Income Ratio | 8.23% | 7.74% | 5.24% | 8.86% | 4.87% | 4.67% | 2.40% | 3.59% | 6.12% | 7.39% | 8.37% | 8.53% | -29.20% | 7.68% | 9.42% | 11.27% | -4.85% | 6.01% | 6.76% | -0.57% | 8.07% | 7.35% | 6.06% | 9.20% | 8.84% | 8.31% | 5.53% | 5.68% | 10.08% | 8.13% | 7.44% | 6.84% | 6.59% | 7.88% | 7.92% | 7.88% | 6.46% |
| EPS | 3.72 | 3.32 | 2.25 | 3.73 | 2.03 | 1.89 | 0.73 | 1.06 | 1.79 | 1.99 | 2.16 | 2.00 | -6.47 | 1.85 | 3.08 | 3.60 | -1.52 | 1.77 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.02 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| EPS Diluted | 3.72 | 3.32 | 2.25 | 3.73 | 1.99 | 1.86 | 0.73 | 1.04 | 1.74 | 1.94 | 2.09 | 1.97 | -6.47 | 1.85 | 3.07 | 3.59 | -1.52 | 1.75 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.01 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| Weighted Avg Shares Out | 66.85M | 67.21M | 67.66M | 67.61M | 65.81M | 65.71M | 65.17M | 57.44M | 58.52M | 60.80M | 61.69M | 62.79M | 62.57M | 62.43M | 61.82M | 61.45M | 61.77M | 62.24M | 62.03M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.47M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
| Weighted Avg Shares Out (Dil) | 66.85M | 67.21M | 67.66M | 67.61M | 67.23M | 66.60M | 65.17M | 58.52M | 60.25M | 62.36M | 63.90M | 63.74M | 62.58M | 62.62M | 62.12M | 61.58M | 61.77M | 62.73M | 62.18M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.66M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
Friedman Industries: Decent Q4 FY24 Results But Still Not Cheap
The company booked a net income of $5 million for Q4 FY24 despite rising processing and warehousing expenses and lower HRC steel prices. The sales volume grew by 13%, and I think it could continue to improve in FY25. However,...
3 Steel Producer Stocks to Escape Industry Headwinds
The Zacks Steel Producers industry has lost momentum after enjoying a strong recovery during the final quarter of 2023 as steel prices have come under pressure since the beginning of this year. Soft demand in China amid the economic slowdown...
HRC member Melnikov spoke about Trepova’s difficult morale in a remand center
Russian FAN agency Alexei Melnikov, member of the Human Rights Council (HRC) to the President of the Russian Federation and secretary of the Moscow Public Supervision Commission, checked the conditions […] The post HRC member Melnikov spoke about Trepova’s difficult...
What should the Russians do after Russia’s withdrawal from the Human Rights Convention and other Council of Europe treaties
Russian President Vladimir Putin on February 28 sign a law according to which the Charter of the Council of Europe (CE), as well as 20 international treaties of this organization, cease to apply to Russia. RTVI spoke with Eva Merkacheva,...
I Am Bullish On Baxter Following Hill-Rom Acquisition
I Am Bullish On Baxter Following Hill-Rom Acquisition
Alcoa Set to Join S&P MidCap 400
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400: Alcoa Corp. (NYSE:AA) will replace Hill-Rom Holdings Inc. (NYSE:HRC) in the S&P MidCap 400 effective prior to the opening of...
3 Stocks to Capitalize on the Buoyant Medical Products Industry
Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-poised to gain from the prospects.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.
Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up
Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.
Hill-Rom (HRC) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Hill-Rom (HRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports